Trial Profile
Phase II trial of cancer vaccine MUC-1 [CVac] in patients with resectable metastatic colorectal cancer.
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2017
Price :
$35
*
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 25 Jun 2013 New trial record
- 24 Jun 2013 The trial protocol will be finalised and applications for regulatory and ethics committee approvals will be initiated in the coming months, according to a Prima Biomed media release.